Cretostimogene Monotherapy Demonstrated 75.2% Complete Response Rate in High-Risk, BCG-Unresponsive Non-Muscle Invasive Bladder Cancer
May 03, 2024 11:23 ET
|
CG Oncology Inc.
Cretostimogene Monotherapy Demonstrated 75.2% Complete Response Rate in High-Risk, BCG-Unresponsive Non-Muscle Invasive Bladder Cancer
[Latest] Global Cancer Cachexia Market Size/Share Worth USD 5.1 Billion by 2033 at a 5.1% CAGR: Custom Market Insights (Analysis, Outlook, Leaders, Report, Trends, Forecast, Segmentation, Growth, Growth Rate, Value)
May 03, 2024 04:30 ET
|
Custom Market Insights
Austin, TX, USA, May 03, 2024 (GLOBE NEWSWIRE) -- Custom Market Insights has published a new research report titled “Cancer Cachexia Market Size, Trends and Insights By Therapeutics (Progestogen,...
Guangzhou Bio-gene Technologies Announces Initiation of Phase I Clinical Trial for BG1805, a CAR-T Targeting CLL-1
May 02, 2024 07:30 ET
|
Bio-Gene Technology Co Ltd
Guangzhou Bio-gene Technologies announces the Initiation of a Phase I Clinical Trial for BG1805, a CAR-T Targeting CLL-1 in patients with AML
Aanastra Inc to Showcase its Peptide-RNA Therapeutics Technology in Multiple Presentations at the American Society for Gene and Cell Therapies (ASGCT) Annual Meeting 2024
May 02, 2024 06:30 ET
|
Aanastra Inc
Aanastra showcases its peptide-RNA therapeutics targeting p53, KRAS and BRCA-1 driven cancers, hemophilia A and PCSK9 for hypercholestrolemia at ASGCT
Revolution Medicines to Report Financial Results for First Quarter 2024 After Market Close on May 8, 2024
May 01, 2024 16:05 ET
|
Revolution Medicines, Inc.
REDWOOD CITY, Calif., May 01, 2024 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (Nasdaq: RVMD), a clinical-stage oncology company developing targeted therapies for patients with RAS-addicted...
Fight Colorectal Cancer Launches ChatCRC: An AI-Powered Chatbot Revolutionizing Colorectal Cancer Support
May 01, 2024 13:04 ET
|
Fight Colorectal Cancer
Springfield, Mo., May 01, 2024 (GLOBE NEWSWIRE) -- Fight Colorectal Cancer (Fight CRC), a leading advocacy organization dedicated to supporting colorectal cancer patients and caregivers, is proud to...
Altamira Therapeutics Announces Filing of Provisional Patent Application for OligoPhore Nanoparticles with siRNA Targeting p65 Protein in Treatment of Cancer and Inflammation
May 01, 2024 08:47 ET
|
Altamira Therapeutics Ltd
Hamilton, Bermuda, May 01, 2024 (GLOBE NEWSWIRE) -- Continued expansion of IP portfolio related to RNA delivery Treatment of rheumatoid arthritis as one of the key therapeutic indications ...
Barinthus Bio Names Experienced Physician, Leon Hooftman, M.D., as Chief Medical Officer
May 01, 2024 07:00 ET
|
Barinthus Biotherapeutics
Barinthus Bio Names Experienced Physician, Leon Hooftman, M.D., as Chief Medical Officer.
Biodexa’s Licensor Emtora to Announce Phase 2 Clinical Trial Results of eRapa™ in Familial Adenomatous Polyposis to be Presented at Prestigious 2024 Digestive Disease Week Annual Meeting
April 30, 2024 11:52 ET
|
Biodexa Pharmaceuticals PLC
April 30, 2024 Biodexa Pharmaceuticals PLC(“Biodexa” or the “Company”) Biodexa’s Licensor Emtora to Announce Phase 2 Clinical Trial Results of eRapa™ in Familial Adenomatous Polyposis to be...
Home Shopping Network Partners with Up-and-Coming Designer
April 30, 2024 06:30 ET
|
Shop LC
Austin, Texas, April 30, 2024 (GLOBE NEWSWIRE) -- Shop LC is thrilled to announce the exclusive launch of Clarté New York, a jewelry brand synonymous with luxury and elegance, founded by acclaimed...